Table 3. Clinical features associated with treatment outcomes of seronegative AIE.
| Estimate | Standard error | p | |
|---|---|---|---|
| Sex | 0.017 | 0.226 | 0.941 |
| Diagnosis | -0.091 | 0.384 | 0.815 |
| Prodromal symptoms | 0.183 | 0.236 | 0.448 |
| CSF inflammation | 0.201 | 0.351 | 0.572 |
| Altered mental status | -0.08 | 0.235 | 0.737 |
| Focal neurological deficit | 0.315 | 0.419 | 0.461 |
| Cognitive dysfunction | -0.115 | 0.272 | 0.677 |
| Acute developmental regression | -0.142 | 0.217 | 0.519 |
| Movement disorder | 0.018 | 0.167 | 0.915 |
| Psychotic disorder | 0.336 | 0.347 | 0.345 |
| Seizure | -0.148 | 0.364 | 0.689 |
| Speech dysfunction | -0.142 | 0.256 | 0.585 |
| Sleep disorder | 0.031 | 0.199 | 0.878 |
| Autonomic dysfunction | -0.407 | 0.235 | 0.097 |
| MRI abnormality | -0.048 | 0.208 | 0.821 |
| Second-line treatment | -0.085 | 0.500 | 0.866 |
| Maintenance treatment | 0.605 | 0.415 | 0.161 |
| Relapse | -0.121 | 0.318 | 0.708 |
| ICU stay | 0.166 | 0.421 | 0.698 |
| Initial mRS score | 0.323 | ||
| 2 | -0.801 | 0.421 | - |
| 3 | -0.513 | 0.402 | - |
| 4 | -0.395 | 0.338 | - |
| mRS score after first-line treatment | 0.006* | ||
| 0 | -2.563 | 0.915 | - |
| 1 | -2.224 | 0.78 | - |
| 2 | -1.277 | 0.737 | - |
| 3 | -0.925 | 0.51 | - |
| 4 | -0.448 | 0.614 | - |
| Time | <0.001* |
*p<0.05.
AIE: autoimmune encephalitis, CSF: cerebrospinal fluid, ICU: intensive care unit, MRI: magnetic resonance imaging, mRS: modified Rankin Scale.